{"nct_id":"NCT03112603","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","status_verified_date":"2025-08","start_date":"2017-06-29","start_date_type":"ACTUAL","primary_completion_date":"2020-05-08","primary_completion_date_type":"ACTUAL","completion_date":"2022-12-15","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["INCY"]}